Amarant Groep

Belkins
The ‘Amarant Groep’ is a large healthcare organisation in the province Noord-Brabant, the Netherlands, providing care to clients in every stage of life. The client perspective is always central. All efforts and innovations are focused on the clients doing it themselves, get involved and their quality of life. The Amarant Groep is the total of the following three brand names.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

BIO-TECHNE AND KANTARO BIOSCIENCES ANNOUNCED THE LAUNCH OF THE COVID-SEROINDEX, A KANTARO QUANTITATIVE SARS-COV-2 IGG ANTIBODY RUO KIT

Bio-Techne | August 04, 2020

news image

Bio-Techne Corporation (NASDAQ:TECH) and the Mount Sinai Health System in New York, through its commercial affiliate Kantaro Biosciences LLC (Kantaro), today announced the anticipated launch of the COVID-SeroIndex, a Kantaro Quantitative SARS-CoV-2 IgG Antibody RUO kit. Bio-Techne and Kantaro will leverage a joint commercialization and distribution team to support rapid distribution of the assay to the vaccine development community. The COVID-SeroIndex test kit is expected to be available ...

Read More

MEDICAL

WESTLAKE VILLAGE BIOPARTNERS LAUNCHES TWO NEW FUNDS TOTALING $500 MILLION TO BUILD AND INVEST IN PROMISING LIFE SCIENCES COMPANIES

Westlake Village BioPartners | December 15, 2020

news image

Westlake Village BioPartners today announced the launch of two new funds totaling $500 million to build and put resources into promising life sciences organizations with transformative therapeutic technologies. The first fund, known as Opportunity 1, is $70 million and permits Westlake to contribute extra Series B or later-round capital into promising organizations they incubated or invested into with their original fund, Westlake BioPartners 1 (WBP1). One example is a begin...

Read More

INTENT DATA IN THE AGE OF DATA REGULATION

DECK 7 | March 23, 2020

news image

Since the implementation of Data Protection Act in 2018, the approach behind the use of data has changed dramatically. Our clients and customers don’t just want a great experience, they also want to make sure they can trust us. Tweet This! And it makes perfect sense in the present time and space. But as data is considered a key factor in positive customer experience, the U.S. brands and agencies have found it to be increasingly complicated to earn customer trust while rem...

Read More

MEDICINAL GENOMICS ANNOUNCES NEW PATHOSEEK® ASPERGILLUS MULTIPLEX ASSAY TO STREAMLINE CANNABIS TESTING

BioSpace | February 27, 2020

news image

Medicinal Genomics (MGC), a pioneer in harnessing cannabis genomics to improve the agricultural productivity, safety, and transparency of cannabis, today announced its new PathoSEEK® 5-Color Aspergillus Multiplex Assay that independently identifies four species of pathogenic Aspergillus— A. flavus, A. fumigatus, A. niger, and A. terreus — on cannabis samples using just one qPCR reaction. This new Aspergillus assay is the first and only qPCR multiplex that can satisfy the Californ...

Read More

Bio-Techne | August 04, 2020

news image

BIO-TECHNE AND KANTARO BIOSCIENCES ANNOUNCED THE LAUNCH OF THE COVID-SEROINDEX, A KANTARO QUANTITATIVE SARS-COV-2 IGG ANTIBODY RUO KIT

Bio-Techne Corporation (NASDAQ:TECH) and the Mount Sinai Health System in New York, through its commercial affiliate Kantaro Biosciences LLC (Kantaro), today announced the anticipated launch of the COVID-SeroIndex, a Kantaro Quantitative SARS-CoV-2 IgG Antibody RUO kit. Bio-Techne and Kantaro will leverage a joint commercialization and distribution team to support rapid distribution of the assay to the vaccine development community. The COVID-SeroIndex test kit is expected to be available ...

Read More

MEDICAL

Westlake Village BioPartners | December 15, 2020

news image

WESTLAKE VILLAGE BIOPARTNERS LAUNCHES TWO NEW FUNDS TOTALING $500 MILLION TO BUILD AND INVEST IN PROMISING LIFE SCIENCES COMPANIES

Westlake Village BioPartners today announced the launch of two new funds totaling $500 million to build and put resources into promising life sciences organizations with transformative therapeutic technologies. The first fund, known as Opportunity 1, is $70 million and permits Westlake to contribute extra Series B or later-round capital into promising organizations they incubated or invested into with their original fund, Westlake BioPartners 1 (WBP1). One example is a begin...

Read More

DECK 7 | March 23, 2020

news image

INTENT DATA IN THE AGE OF DATA REGULATION

Since the implementation of Data Protection Act in 2018, the approach behind the use of data has changed dramatically. Our clients and customers don’t just want a great experience, they also want to make sure they can trust us. Tweet This! And it makes perfect sense in the present time and space. But as data is considered a key factor in positive customer experience, the U.S. brands and agencies have found it to be increasingly complicated to earn customer trust while rem...

Read More

BioSpace | February 27, 2020

news image

MEDICINAL GENOMICS ANNOUNCES NEW PATHOSEEK® ASPERGILLUS MULTIPLEX ASSAY TO STREAMLINE CANNABIS TESTING

Medicinal Genomics (MGC), a pioneer in harnessing cannabis genomics to improve the agricultural productivity, safety, and transparency of cannabis, today announced its new PathoSEEK® 5-Color Aspergillus Multiplex Assay that independently identifies four species of pathogenic Aspergillus— A. flavus, A. fumigatus, A. niger, and A. terreus — on cannabis samples using just one qPCR reaction. This new Aspergillus assay is the first and only qPCR multiplex that can satisfy the Californ...

Read More